Conflict of interest: Nothing to report.
1096-8652/asset/olbannerleft.gif?v=1&s=d9288d4b31f0b8e9a1eb2d195cb165e0aa1d7a97)
1096-8652/asset/olbannerright.gif?v=1&s=78488ac502104a3d829e729353def6ce62dc1e29)
Research Article
You have full text access to this OnlineOpen article
Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival†
Article first published online: 9 OCT 2009
DOI: 10.1002/ajh.21560
Copyright © 2009 Wiley-Liss, Inc.
Additional Information
How to Cite
Lacy, M. Q., Mandrekar, S., Dispenzieri, A., Hayman, S., Kumar, S., Buadi, F., Dingli, D., Litzow, M., Wettstein, P., Padley, D., Kabat, B., Gastineau, D., Rajkumar, S. V. and Gertz, M. A. (2009), Idiotype-pulsed antigen presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. Am. J. Hematol., 84: 799–802. doi: 10.1002/ajh.21560
- †
Publication History
- Issue published online: 23 NOV 2009
- Article first published online: 9 OCT 2009
- Accepted manuscript online: 9 OCT 2009 12:00AM EST
- Manuscript Accepted: 5 OCT 2009
- Manuscript Received: 2 OCT 2009
- Abstract
- References
- Cited By
Abstract
Vaccines are attractive as consolidation therapy after autologous stem cell transplantation (ASCT) for multiple myeloma (MM). We report the results of a phase II trial of the immunotherapeutic, APC8020 (Mylovenge™), given after ASCT for MM. We compared the results with that of other patients with MM who underwent ASCT at Mayo Clinic during the same time period. Twenty-seven patients were enrolled on the trial between July, 1998 and June, 2001, and the outcomes were compared to that of 124 consecutive patients transplanted during the same period, but not enrolled on the trial. The median (range) follow-up for patients still alive from the vaccine trial is 6.5 (2.9–8 years), and 7.1 (6–8 years) in the control group. The median age was 57.4 range (36.1–71.3) in the DB group and 56.4 (range, 30–69) in the trial group. Known prognostic factors including PCLI, B2M, and CRP were comparable between the groups. The median overall survival for the trial patients was 5.3 years (95% CI: 4.0 years—N/A) compared to 3.4 years (95% CI: 2.7–4.6 years) for the DB group (P = 0.02). The median time to progression and progression-free survival for the trial group was similar to the DB group. Although not a controlled trial, the vaccines given after ASCT appear to be associated with improved overall survival compared to historical controls. This approach warrants further investigation to confirm this and define the role of vaccine therapy in myeloma. Am. J. Hematol. 2009. © 2009 Wiley-Liss, Inc.